Graphite Bio

Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo in June 2017 and is headquartered in South San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. It offers eye drop product treatment for presbyopia. The company was founded by James McCollum in July 2013 and is headquartered in Solana Beach, CA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that the first patient has been dosed with GPH101, now called nulabeglogene autogedtemcel (nula-cel), in the company's Phase 1/2 CEDAR trial in people with sickle cell disease (SCD). Nula-cel is an investigational gene

Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ: GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors.

BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4 p.m. ET. The presentation will be webcast live from Graphite Bio's website at www.graphit

Graphite Bio Announces Participation in Jefferies Healthcare Conference

Shares of Graphite Bio are down some 85% from their June 2021 IPO pricing, as its first-ever clinical trial for the treatment of sickle cell disease experienced a six-month delay. The company's potentially curative technology builds on CRISPR Therapeutics by pasting a DNA template into the target gene after it has been cut.

Graphite Bio: Selling For Much Less Than Net Cash

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical data for GPH102, the company's differentiated gene replacement program for beta-thalassemia, in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The

Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and first quarter 2022 financial results. “In the first quarter of 2022, we announced our updated research and development priorities to focus on programs that maximize the capabilities

Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in fireside chats at the following investor conferences: BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 5:40 p.m. ET; 2022 RBC Cap

Graphite Bio Announces Participation in Upcoming Investor Conferences

Harbor Custom Development, Inc.

Sonoma Pharmaceuticals

What to know about buying penny stocks on May 3rd The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Today? 3 to Watch on May 3rd

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GPH101 for the treatment of sickle cell disease (SCD). GPH101 is an investigational next-generation gene-edited autologous

Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that two abstracts will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The abstracts include an oral presentation highlighting the discovery and development of GPH102

Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integration to treat or cure serious diseases, announced today that Josh Lehrer, M.D., M.Phil., chief executive officer of Graphite Bio, and Matthew Porteus, M.D., Ph.D., one of the company's academic founders, will be featured speakers on the “CRISPR and Beyond: Advancing Gene Editing Techniques” panel

Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integration to treat or cure serious diseases, today announced the formation of its Scientific Advisory Board (SAB), which is initially comprised of four experts in stem cell and cancer biology, cell and gene therapy, hematology and immunology. The SAB will provide strategic and scientific counsel as th

Graphite Bio Announces Formation of Scientific Advisory Board

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH) reported recent business progress and fourth quarter and fiscal year 2021 financial results.

Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today that Josh Lehrer, M.D., chief executive officer of Graphite Bio, will be a featured speaker on the gene editing corporate panel discussion at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022, at 12:50 p.m. ET. The panel discussion

Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. today announced the appointment of Alethia Young as chief financial officer.

Graphite Bio Appoints Alethia Young as Chief Financial Officer

Graphite Bio (GRPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Graphite Bio (GRPH) This Earnings Season?

SomaLogic

Two public companies made the BioSpace list of the 30 most promising North American life sciences startups. SomaLogic Inc. ( SLGC , Financial) and Graphite Bio Inc. ( GRPH , Financial) are included in the NextGen Bio “Class of 2022.

SomaLogic, Graphite Bio Make List of Most Promising Life Sciences Companies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #ASH21--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today presented a trial-in-progress poster for the company's Phase 1/2 CEDAR trial for GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease (SCD). The poster is being presented at the 63rd American As

Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today that it will host a virtual Key Opinion Leader webinar on Tuesday, December 14, 2021, at 3 p.m. ET. The event will highlight Graphite Bio's differentiated gene correction approach for sickle cell disease (SCD) using GPH101, the company's lead investiga

Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease

Graphite Bio Initiated the phase 1/2 CEDAR trial using GPH101 for a potential curative treatment of patients with severe sickle-cell disease.

Graphite Bio: An Important Stock To Track In The Gene Editing Space

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that the first patient has been enrolled in the company's Phase 1/2 clinical trial of GPH101, an investigational gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease (S

Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today reported recent business progress and third quarter 2021 financial results. “We continue to remain focused on execution as we work to carry out our vision to develop potential one-time cures for patients with a wide range of serious and life-threatening diseases

Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that information about the company's Phase 1/2 CEDAR trial of GPH101, an investigational therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD), will be presented during a poster session at the 63rd American Soc

Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today that members of the management team will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Thursday, Oct. 28, 2021, at 4:30 p.m. ET. The fireside chat will be webcast live from Graphite Bio's website at www.graphitebio.com

Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit

Absci Corp

Celldex Therapeutics

Toast

ZoomInfo Technologies

FMR LLC, the Boston-based asset management company commonly known as Fidelity, disclosed this month that its top-five trades during September included new buys in Toast Inc. ( TOST , Financial), Graphite Bio Inc. ( GRPH , Financial) and Absci Corp. ( ABSI , Financial), as well as major position boosts in ZoomInfo Technologies Inc. ( ZI , Financial) and Celldex Therapeutics Inc. ( CLDX , Financial).

News for Graphite Bio Stock (GRPH)